Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Radiotherapy for Neoadjuvant Esophageal Squamous Cell Carcinoma
NCT05176002Phase 2Active, not recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Nov 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Union Hospital. Started Nov 2021; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05176002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176002.